Back to Journals » OncoTargets and Therapy » Volume 7

Effective use of everolimus as salvage chemotherapy for ovarian clear cell carcinoma: a case report

Authors Takatori E, Shoji T, Miura Y, Takada A, Takeuchi S, Sugiyama T

Received 20 September 2013

Accepted for publication 8 November 2013

Published 29 January 2014 Volume 2014:7 Pages 165—169


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 6

Eriko Takatori, Tadahiro Shoji, Yuki Miura, Anna Takada, Satoshi Takeuchi, Toru Sugiyama

Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Morioka, Japan

Abstract: A case study using mammalian target of rapamycin complex 1 in recurrent ovarian clear cell carcinoma (CCC) was recently conducted. We report our experience with a patient suffering from recurrent ovarian CCC who achieved long-term disease control with everolimus administration. The patient was a 53-year-old woman who was diagnosed with recurrent ovarian CCC with dissemination throughout the abdominal cavity. Previously, she had received three chemotherapy regimens, but the disease was progressive and she showed no response to treatment. Therefore, oral everolimus administration (everolimus 10 mg/day on days 1–28, a 28-day period comprised one cycle) was started. She was administered six cycles. The antitumor response was stable disease, and grade 3 anemia was observed. Chemotherapy was then switched to gemcitabine/docetaxel therapy. In the middle of the second cycle, a rapid increase in ascitic fluid and CA125 elevation were observed. Thereafter, the patient received best supportive care and died of the disease. Everolimus may inhibit malignant progression of ovarian CCC.

Keywords: mTORC1, ovarian cancer, palliative chemotherapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]